论文部分内容阅读
目的观察来曲唑联合二甲双胍治疗子宫内膜异位症的临床疗效。方法回顾性分析2014年1月—2015年1月河北医科大学附属邢台市人民医院收治的子宫内膜异位症患者82例,根据治疗方式不同,其中40例服用米非司酮患者为对照组,42例服用来曲唑联合二甲双胍患者为观察组,比较两组患者治疗后的子宫内膜异位症的临床疗效、不良反应、血清糖类抗原(CA-125)、血清抗子宫内膜抗体(EMAb)水平。结果治疗后两组患者都有不同程度的改善。相比米非司酮对照组,观察组患者的临床总有效率突出,同时血清CA-125和EMAb水平下降较为显著,有统计学意义(P<0.05)。两组间不良反应差异无统计学意义(P>0.05)。结论来曲唑联合二甲双胍治疗子宫内膜异位症临床效果显著,值得在临床进一步研究。
Objective To observe the clinical efficacy of letrozole and metformin in the treatment of endometriosis. Methods A retrospective analysis of 82 patients with endometriosis admitted to Xingtai People’s Hospital affiliated to Hebei Medical University from January 2014 to January 2015 was conducted. According to the different treatment methods, 40 patients taking mifepristone as control group , 42 patients taking letrozole combined with metformin as the observation group, the clinical efficacy, adverse reactions, serum carbohydrate antigen (CA-125), serum anti-endometrial antibody (EMAb) level. Results After treatment, both groups of patients had different degrees of improvement. Compared with the mifepristone control group, the total effective rate of the patients in the observation group was prominent, while the serum CA-125 and EMAb levels were significantly decreased (P <0.05). Adverse reactions between the two groups showed no significant difference (P> 0.05). Conclusion Letrozole combined with metformin in the treatment of endometriosis has a significant clinical effect and deserves further clinical study.